Clinical Trials on Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Total 1299 results

Fred Hutchinson Cancer Center
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers

HIV Infection | Hematopoietic and Lymphoid Cell Neoplasm | Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Erythroid Leukemia | Acute Megakaryoblastic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Myelodysplastic Syndrome With Excess Blasts | Chronic Myelogenous Leukemia, BCR-ABL1... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Acute Myeloid Leukemia | Recurrent Hodgkin Lymphoma | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Aplastic Anemia | Recurrent Non-Hodgkin... and other conditions

United States
Children's Oncology Group
Pfizer; Erasmus Medical Center; Dutch Childhood Oncology Group; Innovative Therapies...

Active, not recruiting

Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia

Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Blastic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome Positive CML

United States
University of California, Irvine

Recruiting

Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia

Chronic Myeloid Leukemia | Chronic Phase Chronic Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia

Accelerated Phase Chronic Myelogenous Leukemia (CML) | Blast Phase Chronic Myelogenous Leukemia (CML) | Chronic Phase Phase Chronic Myelogenous Leukemia (CML) | Philadelphia Chromosome Positive (Ph+) Phase Chronic Myelogenous Leukemia (CML)

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Terminated

An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)

Leukemia

United States
Astex Pharmaceuticals, Inc.
Eisai Inc.

Completed

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Chronic Myelogenous Leukemia

United States, Canada
Sheba Medical Center

Unknown

Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy

Leukemia, Myeloid, Philadelphia-Positive

Israel
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia

Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Hematopoietic and Lymphoid Cell Neoplasm | Diffuse Large B-Cell Lymphoma | Refractory Hodgkin Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Plasma Cell Myeloma | Refractory Chronic Lymphocytic Leukemia | Myelodysplastic/Myeloproliferative Neoplasm | Chronic Phase Chronic Myelogenous... and other conditions

United States, Germany, Italy
Novartis Pharmaceuticals

Completed

Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial

Chronic Myelogenous Leukemia

Poland
Novartis Pharmaceuticals

No longer available

Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

Chronic Myelogenous Leukemia

Canada
Florida International University
National Institute on Minority Health and Health Disparities (NIMHD); Nicklaus... and other collaborators

Recruiting

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

Recurrent Childhood Ependymoma | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Childhood Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma | Recurrent Childhood Large... and other conditions

United States
Pfizer

Completed

Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

Chronic Myeloid Leukaemia

Hungary
Pfizer
pH Associates

Completed

A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands

Chronic Myeloid Leukaemia

United Kingdom
Novartis Pharmaceuticals

Completed

Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia

Chronic Myeloid Leukaemia

United Kingdom
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Juvenile Myelomonocytic Leukemia | Chronic Lymphocytic Leukemia | Secondary Acute Myeloid Leukemia | Childhood Acute Lymphoblastic Leukemia | Prolymphocytic Leukemia | Hairy Cell Leukemia | Acute Undifferentiated Leukemia | Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Childhood Acute Myeloid... and other conditions

United States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
National Cancer Institute (NCI)

Completed

3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Accelerated Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Philadelphia Chromosome Negative Chronic Myelogenous... and other conditions

United States
European Society for Blood and Marrow Transplantation
Hoffmann-La Roche; Amgen

Completed

Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation

Acute Leukemia | Myelodysplastic Syndrome | Chronic Myelogenous Leukemia

Germany
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Intra-Osseous Co-Transplant of UCB and hMSC

Myelodysplastic Syndromes | Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Myelofibrosis | Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Refractory Chronic Lymphocytic Leukemia | Refractory Non-Hodgkin Lymphoma | Lymphoid Malignancies | Relapsed Non-Hodgkin Lymphoma and other conditions

United States
Medical College of Wisconsin
Memorial Sloan Kettering Cancer Center; Dana-Farber Cancer Institute; University... and other collaborators

Completed

The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)

Leukemia, Myeloid, Chronic

United States
Tehran University of Medical Sciences

Completed

Safety Assessment of a Multipeptide-gene Vaccine in CML

Leukemia, Myeloid, Chronic

Iran, Islamic Republic of
Shenzhen Second People's Hospital

Recruiting

TKI Discontinuation in CML Patients of China (TFR_china)

Leukemia | Myelogenous | Chronic | BCR-ABL (Breakpoint Cluster Region-abelson Murine Leukemia) | Positive

China
Ministry of Health, Malaysia

Unknown

Malaysia Stop Tyrosine Kinase Inhibitor Trial (MSIT)

Leukemia, Chronic Myeloid

Malaysia
S*BIO

Completed

A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies

Myelodysplastic Syndromes | Myelofibrosis | Chronic Myelomonocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

Acute Myeloid Leukemia | Hodgkin Lymphoma | Recurrent Hodgkin Lymphoma | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Acute Leukemia | Myelodysplastic Syndrome | Refractory Myelodysplastic Syndrome and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Personalized NK Cell Therapy in CBT

Recurrent Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Myelodysplastic Syndrome... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); The Wayne D. Kuni and Joan E. Kuni Foundation

Completed

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

Diffuse Large B-Cell Lymphoma | Acute Myeloid Leukemia | Refractory Hodgkin Lymphoma | Previously Treated Myelodysplastic Syndrome | Recurrent Mantle Cell Lymphoma | Waldenstrom Macroglobulinemia | Acute Lymphoblastic Leukemia | Refractory Plasma Cell Myeloma | Recurrent Small Lymphocytic Lymphoma | Refractory... and other conditions

United States
Novartis Pharmaceuticals

Active, not recruiting

Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation (AIM4CML)

Chronic Myelogenous Leukemia - Chronic Phase

United States
Gesellschaft fur Medizinische Innovation - Hamatologie...
Crolll Gmbh

Completed

Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation (Crescendo)

Chronic Myelogenous Leukemia (CML)

Germany
Florida International University
Nicklaus Children's Hospital f/k/a Miami Children's Hospital

Completed

Ex Vivo Drug Sensitivity Testing and Mutation Profiling

Recurrent Childhood Ependymoma | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Childhood Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma | Recurrent Childhood Large... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Diffuse Large B-Cell Lymphoma | Acute Myeloid Leukemia | Refractory Hodgkin Lymphoma | Waldenstrom Macroglobulinemia | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Prolymphocytic Leukemia | Refractory... and other conditions

United States, Germany, Denmark
Novartis Pharmaceuticals

Terminated

Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations (MACS1148)

CML | Philadelphia Chromosome Positive (Ph+) | Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough Levels

United States
University of Maryland, Baltimore
National Cancer Institute (NCI)

Completed

R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia

Leukemia

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia

Leukemia

United States
First Affiliated Hospital of Harbin Medical University

Unknown

Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients (HU)

Leukemia, Chronic Myeloid

China
Agenus Inc.

Terminated

AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™

Leukemia, Myeloid, Chronic

United States, United Kingdom
King Faisal Specialist Hospital & Research Center

Unknown

Prospective Database for Chronic Myelogenous Leukemia

Leukemia, Myeloid, Chronic
Nanfang Hospital of Southern Medical University

Recruiting

Dasatinib Down-regulates the Expression of PD-1 and Enhances Killing pH + Leukemia Stem Cells

Chronic Myeloid Leukemia

China
Fundación Teófilo Hernando, Spain

Recruiting

Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

Spain
The University of Hong Kong

Recruiting

The Hong Kong CML Registry

Chronic Myeloid Leukemia

Hong Kong
University of Jena

Completed

TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study (TIGER)

Chronic Myeloid Leukemia

Germany, Switzerland, Czechia
Takeda

Completed

A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia

Leukemia

United States
Novartis Pharmaceuticals

Completed

Study Conducted Among Patients With CML

Chronic Myeloid Leukemia

United States
Tanta University

Completed

Dynamic Changes in the Levels of sCD62L and SPARC in Chronic Myeloid Leukemia Patients During Imatinib Treatment

Chronic Myeloid Leukemia

Egypt
Gruppo Italiano Malattie EMatologiche dell'Adulto

Active, not recruiting

Bosutinib in Elderly Chronic Myeloid Leukemia (BEST)

Chronic Myeloid Leukemia

Italy
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)

Chronic Myeloid Leukemia

United States, Belgium, France, Korea, Republic of
University of British Columbia
Bristol-Myers Squibb

Completed

A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With Imatinib

Chronic Myeloid Leukemia

Canada
Novartis Pharmaceuticals

Completed

To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib

Chronic Myeloid Leukemia

United Kingdom, Germany
University Health Network, Toronto

Unknown

Allogeneic SCT for CML, TKI Failure After TKI Failure

Chronic Myeloid Leukemia

Canada

Clinical Trials on Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations